Provided by Tiger Trade Technology Pte. Ltd.

Kalvista Pharmaceuticals Inc

16.94
-0.4400-2.53%
Post-market: 16.940.00000.00%17:09 EDT
Volume:844.25K
Turnover:14.35M
Market Cap:856.25M
PE:-4.29
High:18.20
Open:17.50
Low:16.47
Close:17.38
52wk High:19.00
52wk Low:9.24
Shares:50.55M
Float Shares:27.81M
Volume Ratio:0.61
T/O Rate:3.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9460
EPS(LYR):-3.6945
ROE:-190.18%
ROA:-60.98%
PB:20.99
PE(LYR):-4.59

Loading ...

KalVista Pharmaceuticals Reports $49 Million Full-Year 2025 Revenue for EKTERLY Launch

Reuters
·
Jan 09

Kalvista Pharmaceuticals Provides Update on Strong Ekterly® Launch With Preliminary Fourth Quarter and Full Year 2025 Revenue Results

THOMSON REUTERS
·
Jan 09

Kalvista Pharmaceuticals Inc - Ekterly Generates $35 Mln in Q4 Revenue

THOMSON REUTERS
·
Jan 09

KalVista Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
Jan 06

Japan Approves KalVista's EKTERLY as First Oral On-Demand HAE Treatment

Reuters
·
Dec 22, 2025

Kalvista Pharmaceuticals Announces Approval of Ekterly® (Sebetralstat) in Japan, First and Only Oral on-Demand Treatment for Hereditary Angioedema

THOMSON REUTERS
·
Dec 22, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Dec 04, 2025

KalVista Pharmaceuticals Price Target Maintained With a $28.00/Share by Needham

Dow Jones
·
Dec 04, 2025

Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows

Benzinga_recent_news
·
Dec 03, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Dec 01, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 28, 2025

KalVista Pharmaceuticals Is Maintained at Market Outperform by Citizens

Dow Jones
·
Nov 11, 2025

Kalvista Pharmaceuticals Highlights EKTERLY Oral Treatment Advances for Hereditary Angioedema in New Presentation

Reuters
·
Nov 11, 2025

KalVista Pharmaceuticals reports $13.7 million in net product revenue for third quarter

Reuters
·
Nov 11, 2025

Kalvista Pharmaceuticals Inc - Qtrly Net Loss per Share, Basic and Diluted $0.92

THOMSON REUTERS
·
Nov 11, 2025

Kalvista Pharmaceuticals Inc - Net Product Revenue $13.7 Mln in Q3

THOMSON REUTERS
·
Nov 11, 2025

Top News Today/Canada: Barrick's Interim CEO Gets to Work

Dow Jones
·
Nov 11, 2025

KalVista Unveils New Data Showing High Patient Satisfaction With Oral HAE Drug EKTERLY

Reuters
·
Nov 06, 2025

KalVista Pharmaceuticals to Present at Stifel Healthcare Conference

Reuters
·
Nov 05, 2025

Kalvista Pharmaceuticals Inc. to Release Third Quarter Financial Results

Reuters
·
Nov 03, 2025